David Kirn, the President and Chief Executive Officer of 4D Molecular Therapeutics, Inc., has sold a significant number of shares in the company. On October 5, 2026, Kirn disposed of over 58,000 shares of common stock, marking a notable transaction in the biotechnology sector.

This sale is part of a 10b5-1 trading plan that Kirn adopted on January 9, 2026. Such plans allow executives to set up a predetermined schedule for selling shares, helping to avoid any potential allegations of insider trading. The move is indicative of ongoing adjustments in executive holdings, which can reflect various personal or financial strategies.

Background

4D Molecular Therapeutics, Inc. is a biotechnology company focused on developing innovative gene therapies. The company operates within the Biological Products (No Diagnostic Substances) industry, classified under the SIC code 2836. Recent filings indicate that Kirn has been actively managing his stock holdings, with this latest transaction following several others in recent months.

What the Filing Says

The SEC filing reveals that Kirn sold 58,061 shares at a weighted average price of approximately $12.92 per share, with the transaction executed in multiple trades. Additionally, he sold 272 shares at an average price of $13.61. Following these transactions, Kirn retains ownership of 709,425 shares. The filing states, "Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026." This highlights the structured nature of the sales.

Impact

This sale may affect the perception of 4D Molecular Therapeutics among investors and analysts, as executive stock sales can sometimes be interpreted as a lack of confidence in the company's future. However, the use of a 10b5-1 plan typically reassures stakeholders that the sales were pre-planned and not influenced by insider information. The biotechnology industry may also see similar actions from other executives as they navigate market conditions and personal financial strategies.

What's Next

The filing does not say what happens next, but it is likely that Kirn will continue to manage his holdings in accordance with his trading plan. Investors will be watching for any further disclosures regarding executive transactions at 4D Molecular Therapeutics.